85 related articles for article (PubMed ID: 24103886)
1. [Chinese guidelines for diagnosis and treatment of diffuse large B cell lymphoma(2013)].
;
Zhonghua Xue Ye Xue Za Zhi; 2013 Sep; 34(9):816-9. PubMed ID: 24103886
[No Abstract] [Full Text] [Related]
2. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
Marcus R; Davies A; Ando K; Klapper W; Opat S; Owen C; Phillips E; Sangha R; Schlag R; Seymour JF; Townsend W; Trněný M; Wenger M; Fingerle-Rowson G; Rufibach K; Moore T; Herold M; Hiddemann W
N Engl J Med; 2017 Oct; 377(14):1331-1344. PubMed ID: 28976863
[TBL] [Abstract][Full Text] [Related]
3. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification.
Cheson BD; Fisher RI; Barrington SF; Cavalli F; Schwartz LH; Zucca E; Lister TA; ; ; ; ; ; ; ; ; ; ; ; ; ; ;
J Clin Oncol; 2014 Sep; 32(27):3059-68. PubMed ID: 25113753
[TBL] [Abstract][Full Text] [Related]
4. [Chinese guidelines for diagnosis and treatment of follicular lymphoma (2020)].
;
Zhonghua Xue Ye Xue Za Zhi; 2020 Jul; 41(7):537-544. PubMed ID: 32810959
[No Abstract] [Full Text] [Related]
5. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study.
Flinn IW; van der Jagt R; Kahl B; Wood P; Hawkins T; MacDonald D; Simpson D; Kolibaba K; Issa S; Chang J; Trotman J; Hallman D; Chen L; Burke JM
J Clin Oncol; 2019 Apr; 37(12):984-991. PubMed ID: 30811293
[TBL] [Abstract][Full Text] [Related]
6. The 2016 revision of the World Health Organization classification of lymphoid neoplasms.
Swerdlow SH; Campo E; Pileri SA; Harris NL; Stein H; Siebert R; Advani R; Ghielmini M; Salles GA; Zelenetz AD; Jaffe ES
Blood; 2016 May; 127(20):2375-90. PubMed ID: 26980727
[TBL] [Abstract][Full Text] [Related]
7. [How I diagnose and treat diffuse large B cell lymphoma].
Zhao WL; Zhang MC; Fu D
Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):978-984. PubMed ID: 35045667
[No Abstract] [Full Text] [Related]
8. AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma.
Leonard JP; Trneny M; Izutsu K; Fowler NH; Hong X; Zhu J; Zhang H; Offner F; Scheliga A; Nowakowski GS; Pinto A; Re F; Fogliatto LM; Scheinberg P; Flinn IW; Moreira C; Cabeçadas J; Liu D; Kalambakas S; Fustier P; Wu C; Gribben JG;
J Clin Oncol; 2019 May; 37(14):1188-1199. PubMed ID: 30897038
[TBL] [Abstract][Full Text] [Related]
9. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma.
Morschhauser F; Fowler NH; Feugier P; Bouabdallah R; Tilly H; Palomba ML; Fruchart C; Libby EN; Casasnovas RO; Flinn IW; Haioun C; Maisonneuve H; Ysebaert L; Bartlett NL; Bouabdallah K; Brice P; Ribrag V; Daguindau N; Le Gouill S; Pica GM; Martin Garcia-Sancho A; López-Guillermo A; Larouche JF; Ando K; Gomes da Silva M; André M; Zachée P; Sehn LH; Tobinai K; Cartron G; Liu D; Wang J; Xerri L; Salles GA;
N Engl J Med; 2018 Sep; 379(10):934-947. PubMed ID: 30184451
[TBL] [Abstract][Full Text] [Related]
10. Rituximab and the risk of transformation of follicular lymphoma: a retrospective pooled analysis.
Federico M; Caballero Barrigón MD; Marcheselli L; Tarantino V; Manni M; Sarkozy C; Alonso-Álvarez S; Wondergem M; Cartron G; Lopez-Guillermo A; Issa D; Morschhauser F; Alcoceba M; Kimby E; Rusconi C; Chamuleau M; Holte H; Lockmer S; Montoto S; Gomes da Silva M; Aurer I; Zucca E; Paszkiewicz-Kozik E; Minoia C; Skrypets T; Blaker YN; Salles G; Coiffier B;
Lancet Haematol; 2018 Aug; 5(8):e359-e367. PubMed ID: 30078408
[TBL] [Abstract][Full Text] [Related]
11. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.
Schmitz R; Wright GW; Huang DW; Johnson CA; Phelan JD; Wang JQ; Roulland S; Kasbekar M; Young RM; Shaffer AL; Hodson DJ; Xiao W; Yu X; Yang Y; Zhao H; Xu W; Liu X; Zhou B; Du W; Chan WC; Jaffe ES; Gascoyne RD; Connors JM; Campo E; Lopez-Guillermo A; Rosenwald A; Ott G; Delabie J; Rimsza LM; Tay Kuang Wei K; Zelenetz AD; Leonard JP; Bartlett NL; Tran B; Shetty J; Zhao Y; Soppet DR; Pittaluga S; Wilson WH; Staudt LM
N Engl J Med; 2018 Apr; 378(15):1396-1407. PubMed ID: 29641966
[TBL] [Abstract][Full Text] [Related]
12. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben J; Lennard A; Lugtenburg PJ; Dimier N; Wassner-Fritsch E; Fingerle-Rowson G; Cheson BD
Lancet Oncol; 2016 Aug; 17(8):1081-1093. PubMed ID: 27345636
[TBL] [Abstract][Full Text] [Related]
13. Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations.
Siddiqi IN; Friedman J; Barry-Holson KQ; Ma C; Thodima V; Kang I; Padmanabhan R; Dias LM; Kelly KR; Brynes RK; Kamalakaran S; Houldsworth J
Mod Pathol; 2016 Jun; 29(6):570-81. PubMed ID: 26965583
[TBL] [Abstract][Full Text] [Related]
14. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.
Zhou Z; Sehn LH; Rademaker AW; Gordon LI; Lacasce AS; Crosby-Thompson A; Vanderplas A; Zelenetz AD; Abel GA; Rodriguez MA; Nademanee A; Kaminski MS; Czuczman MS; Millenson M; Niland J; Gascoyne RD; Connors JM; Friedberg JW; Winter JN
Blood; 2014 Feb; 123(6):837-42. PubMed ID: 24264230
[TBL] [Abstract][Full Text] [Related]
15. [Distribution and prognostic value of LymphGen genotyping in patients with diffuse large B-cell lymphoma].
Zhang F; Renaguli A; Qi XL; Kou Z; Zhai SS; Tan W; Muhebaier A; Nie YL; Li Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Apr; 43(4):305-310. PubMed ID: 35680629
[No Abstract] [Full Text] [Related]
16. [The consensus for differential diagnosis of B cell chronic lymphoproliferative diseases in China (2018 edition)].
; ;
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):359-365. PubMed ID: 29779341
[No Abstract] [Full Text] [Related]
17. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.
Eichhorst B; Fink AM; Bahlo J; Busch R; Kovacs G; Maurer C; Lange E; Köppler H; Kiehl M; Sökler M; Schlag R; Vehling-Kaiser U; Köchling G; Plöger C; Gregor M; Plesner T; Trneny M; Fischer K; Döhner H; Kneba M; Wendtner CM; Klapper W; Kreuzer KA; Stilgenbauer S; Böttcher S; Hallek M; ;
Lancet Oncol; 2016 Jul; 17(7):928-942. PubMed ID: 27216274
[TBL] [Abstract][Full Text] [Related]
18. Real-world data for lenalidomide maintenance in responding patients of diffuse large B-cell lymphoma.
Wang X; Yu L; Jiang X; Ding K
Cancer Med; 2023 May; 12(9):10553-10562. PubMed ID: 36912128
[TBL] [Abstract][Full Text] [Related]
19. T-cell immunoglobulin mucin molecule-3, transformation growth factor β, and chemokine-12 and the prognostic status of diffuse large B-cell lymphoma.
Wu H; Sun HC; Ouyang GF
World J Clin Cases; 2022 Nov; 10(32):11804-11811. PubMed ID: 36405294
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
